E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000803 |
E.1.2 | Term | Acute heart failure |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effects on hemodynamic variables of RLX030 administered as i.v. infusion in patients with acute heart failure |
|
E.2.2 | Secondary objectives of the trial |
- To assess the on-set and off-set effects of RLX030 administered as i.v. infusion in patients with acute heart failure
- To assess the effects of RLX030 administered as i.v. infusion on diuresis and creatinine clearance in patients with acute heart failure
- To assess the effects of RLX030 administered as i.v. infusion on central aortic systolic pressure and radial arterial pulse waveform in patients with acute heart failure
- To assess the pharmacokinetics of RLX030 administered as i.v. infusion in patients with acute heart failure
- To assess the overall safety and tolerability of RLX030 administered as i.v. infusion in patients with acute heart failure
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients admitted to hospital or who require admission to hospital for management of acute heart failure with shortness of breath at rest or minimal exertion
- stabilized within 2 days after admission
- normal or elevated systolic blood pressure
- elevated pulmonary capilary wedge pressure measured by Swan-Ganz catheterization
|
|
E.4 | Principal exclusion criteria |
- severe renal impairment
- significant liver impairment
- significant lung impairment
- significant heart valve dysfunction or arrythmias
- myocardial infarction or acute coronary syndrome within th elast 45 days
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Pulmonary capillary wedge pressure (PCWP),
- Right atrial pressure (RAP),
- Systolic and diastolic pulmonary artery pressure (PAP),
- Pulmonary oxygen saturation (pO2) and
- Cardiac output (CO)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At baseline, at 30 minutes, and 2, 4, 6, 8, 20, 22, and 24 hours after start of infusion of study drug |
|
E.5.2 | Secondary end point(s) |
a.Non-invasive measurement of central aortic systolic pressure and radial arterial pulse waveform
b.Pharmacokinetics
c.Total urine volume
d.Safety and tolerability
e.Sodium and creatinine excretion
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
a. At baseline, at 30 minutes, and 2, 4, 6, 8, 20, 22, and 24 hours after start of infusion of study drug
b. At baseline, at 10, 30 minutes, and 2, 8, 20, 22, 24, 27 and 44 hoursand on Day 30 after start of infusion of study drug
c.AE/SAE monitoring
d. Safety biochemistry and hematology samples taken at baseline and at 8, 20, and 24 hours after start of infusion of study drug and whenever clinically indicated. Blood pressure measured together with central aortic systolic pressure (see. a.) and ECG taken at baseline and at 8, 20, 24, and 44 hours after start of infusion of study drug
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Germany |
Italy |
Poland |
Russian Federation |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patient’s last visit |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 0 |